Skip to content
value.today

Niki BioSolutions, Inc.

NIKI
$6 Mlast known market cap, Mar 2026 — no current value
Compare
World rank
—
no current market cap
Revenue
—
For year ending December-2025
Net income
$-1 M
SEC filing
Employees
—

Niki BioSolutions, Inc. in brief

Niki BioSolutions, Inc. is a listed company in the Biotechnology industry, based in the UK. It was founded in 2010. Its last known market value was $6 M (March 2026); there is no current figure. Its shares trade under the symbol NIKI (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Niki BioSolutions, Inc.

Aptorum Group is a Pharmaceutical company dedicated to developing and commercializing novel therapeutics to tackle unmet medical needs. It is pursuing therapeutic projects in orphan diseases, infectious diseases, metabolic diseases, woman health and other disease areas. The headquarters is in UK.

Niki BioSolutions, Inc. timeline

2 events, 2010–2018
  1. 2010
  2. 🏁
    · approximate
    Founded
  3. 2018
  4. 🔔
    · approximate
    Initial public offering on Nasdaq

Events of Niki BioSolutions, Inc. from the company record. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$122 M$243 M$365 M$486 M2020202120222023202420252026

World rank over time

▼ down 1,501 places since 2020
2020-01-01: #11552#11,55220202021-01-01: #18827#18,82720212022-01-07: #25515#25,51520222022-12-25: #28733#28,73320222023-07-30: #32023#32,02320232024-01-05: #31061#31,06120242026-03-08: #13053#13,0532026

Rank in UK: #367 (Jan 2020) · #631 (Jan 2021) · #1,165 (Jan 2022) · #1,119 (Dec 2022) · #1,264 (Jul 2023) · #1,154 (Jan 2024) · #30 (Mar 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
—
Free cash flow yield
—
Net margin
—
Operating margin
—
Return on equity
-5.9%
Liabilities / assets
26.2%
Net debt
$-5M
Revenue growth
-66.9%
R&D / revenue
1209.3%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue —, net income $-15M—FY18Fiscal year ending Dec 2019: revenue —, net income $-20M—FY19Fiscal year ending Dec 2020: revenue —, net income $5M—FY20Fiscal year ending Dec 2021: revenue $2M, net income $-25M$2MFY21Fiscal year ending Dec 2022: revenue $1M, net income $-10M$1MFY22Fiscal year ending Dec 2023: revenue $0M, net income $-3M$0MFY23Fiscal year ending Dec 2024: revenue —, net income $-4M—FY24Fiscal year ending Dec 2025: revenue —, net income $-1M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025———$-1M—
Dec 2024———$-4M—
Dec 2023$0M-66.9%—$-3M-655.8%
Dec 2022$1M-15.6%—$-10M-753.8%
Dec 2021$2M——$-25M-1626.6%
Dec 2020———$5M—
Dec 2019———$-20M—
Dec 2018———$-15M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-2M——$-0.19—
Dec 2024$-1M——$-0.78—
Dec 2023$-8M$0M$-8M$-0.62—
Dec 2022$-12M$0M$-13M$-2.75—
Dec 2021$-15M$0M$-15M$-7.15—
Dec 2020$-16M$0M$-16M$2.00—
Dec 2019$-13M$1M$-14M$-0.64—
Dec 2018$-10M$6M$-16M$-0.53—

Annual results

Revenue
—
Operating income
—
Net income
$-1 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$19 M
Total liabilities
$5 M
Total equity
$23 M

As of December-2025

Top 3 institutional investors in Niki BioSolutions, Inc.#

As of Sep 30, 2026
3 institutions held 17,662 shares on Sep 30, 2026. Source: SEC Form 13F filings, filed through Nov 13, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 3 largest institutional investors in Niki BioSolutions, Inc.
#InstitutionShares heldChange (shares)ValueFiled
1HRT Financial LP15,462New$0 MNov 13, 2026
2UBS Group AG2,198New$0 MNov 10, 2026
3Jpmorgan Chase & Co2New$0 MNov 12, 2026

Insider trading at Niki BioSolutions, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
1
since
Niki BioSolutions, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Alidad MireskandariPresident & COOOption exercise+20,000——20,000Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Niki BioSolutions, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
1,717
1 days to cover
Shares sold short, last 24 reportsAll stocks →

Trading halts

  • 2026-07-17 23:50 UTC, code D, resumed 04:00 UTC
  • 2025-10-10 13:54 UTC, code LUDP, resumed 13:59 UTC
  • 2025-08-21 13:54 UTC, code LUDP, resumed 13:59 UTC
  • 2025-07-16 14:39 UTC, code LUDP, resumed 14:44 UTC
  • 2025-07-16 14:02 UTC, code LUDP, resumed 14:12 UTC

Fails to deliver

  • : 120 shares at $4.72
  • : 1,133 shares at $0.82
  • : 2,831 shares at $0.81
  • : 3,640 shares at $0.83
  • : 8,920 shares at $0.87

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Niki BioSolutions, Inc. scorecard#

Passes 0 of the 8 checks that could be worked out. Fiscal year 2025.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-0.19 vs -0.78Diluted EPS -0.19 in fiscal 2025 against -0.78 the year before (report's currency).
    • ✗Net income higher than five years earlier-$1 M-$1 M in fiscal 2025 against $5 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$1 MNet income -$1 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-6.2%-6.2% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health0 of 2
    • ✗Short-term assets cover short-term liabilities0.8×Current ratio 0.78 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year34.8%Diluted shares up 34.8% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Niki BioSolutions, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Niki BioSolutions, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018
Income statement
Revenue——4311,2961,542———
Cost of revenue——4211,2161,460———
Research and development3532,1955,1989,22010,87011,5876,9393,101
General and administrative5736691,9315,2205,4094,8537,3734,920
Operating expenses——3118,80520,74921,18718,73410,712
Total costs and expenses—3,94111,15618,80520,749———
Other non-operating income (expense)441−2176,3835,984−7,90725,196−1,918−4,806
Income before tax−1,376−4,158−4,341—————
Income from continuing operations−1,376−4,158−4,341—————
Net income including minority interests−1,376−4,158−4,341−11,525−27,1144,920−20,117−15,134
Minority interests' share of net income−13110−1,516−1,726−2,0662,1471,430r303r
Net income attributable to shareholders−1,363−4,268−2,825−9,800r−25,048r4,920r−20,117r−14,832
Earnings per share, basic-0.19-0.78-0.62-2.75-7.15r2.03r-0.64-0.53
Earnings per share, diluted-0.19-0.78-0.62-2.75-7.15r2.00r-0.64-0.53
Shares, weighted average (basic)7.45.54.53.63.5r3.1r2928
Shares, weighted average (diluted)7.45.54.53.63.5r3.2r2928
Balance sheet
Cash and cash equivalents3,4538742,0051,8838,1313,4955,18912,007
Short-term investments———102237—1,0631,014
Receivables——481747962412.8
Inventory———2836393431
Other current assets140854227445931,3791,079—
Current assets3,5939602,4767,06812,68833,6578,03328,723
Property, plant and equipment——1,6642,8253,7314,6867,0934,261
Right-of-use (leased) assets——182347154547——
Other intangible assets——1477538809651,3121,410
Investments in associates——7700———
Long-term investments15,09915,09916,0999,745————
Total assets18,69116,13020,64020,86721,90744,23123,95445,075
Accounts payable1,0729191,8946,1674,1733,2412,587—
Current liabilities4,5944,3392,09912,5034,3773,8692,67512,185
Long-term debt———1302962962953,417
Lease liabilities (non-current)—14993124155——
Total liabilities4,9004,3535,25713,0344,4016,0799,10212,329
Retained earnings−73,793−72,430−68,162−65,337−55,538−30,489−37,556−17,379
Shareholders' equity23,11521,13524,84615,71223,60741,83416,36133,114
Minority interests−9,371−9,357−9,463−7,879−6,101−3,682−1,509−369
Total equity13,74511,77715,3837,83317,50638,15214,85232,746
Total liabilities and equity18,69116,13020,64020,86721,90744,23123,95445,075
Cash-flow statement
Depreciation and amortization—2551,1251,2081,1931,3351,300682
Share-based compensation——1,2651,6471,6821,4791,613—
Cash from operating activities−1,837−1,190−7,724−12,319−14,652−15,932−13,383−10,036
Capital expenditure——−3.0−187−132−161−837−5,647
Intangible assets bought————−6.0—−70−418
Acquisitions, net of cash acquired————−114———
Cash from investing activities—596252,44516,5071,842−108−6,062
Shares issued3,070—1,576—4,00017,497—11,054
Cash from financing activities4,415—4,0926,6252,78112,422−7,32325,479
Change in cash———−3,2494,636−1,668−20,8149,381
Report20-F20-F20-F20-F20-F20-F20-F/A20-F

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Dec 31, 2025. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

How Niki BioSolutions, Inc. compares in Biotechnology

  • Revenue growth-66.9% · higher than 12% of 438

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Niki BioSolutions, Inc.🇬🇧$6 M——-66.9%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Mar 8, 2026 (last known)
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 16, 2026

Figures from SEC filing, value.today research; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Niki BioSolutions, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Niki BioSolutions, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Niki BioSolutions, Inc.? Suggest a correction